Bluestein R H & Co. Purchases 20,750 Shares of ABIOMED, Inc. (ABMD)

Bluestein R H & Co. raised its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 728.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,600 shares of the medical equipment provider’s stock after buying an additional 20,750 shares during the quarter. Bluestein R H & Co. owned about 0.05% of ABIOMED worth $3,979,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ABMD. Dimensional Fund Advisors LP increased its holdings in shares of ABIOMED by 4.6% during the first quarter. Dimensional Fund Advisors LP now owns 138,140 shares of the medical equipment provider’s stock valued at $17,295,000 after acquiring an additional 6,134 shares in the last quarter. Aperio Group LLC increased its holdings in shares of ABIOMED by 6.9% during the second quarter. Aperio Group LLC now owns 13,198 shares of the medical equipment provider’s stock valued at $1,891,000 after acquiring an additional 853 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of ABIOMED during the second quarter valued at $284,000. Great West Life Assurance Co. Can increased its holdings in shares of ABIOMED by 4.4% during the second quarter. Great West Life Assurance Co. Can now owns 25,014 shares of the medical equipment provider’s stock valued at $3,581,000 after acquiring an additional 1,063 shares in the last quarter. Finally, Lebenthal Lisanti Capital Growth LLC bought a new position in shares of ABIOMED during the second quarter valued at $390,000. 90.75% of the stock is owned by institutional investors and hedge funds.

In other news, VP Michael G. Howley sold 10,000 shares of ABIOMED stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the transaction, the vice president now directly owns 56,757 shares of the company’s stock, valued at approximately $10,139,070.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dorothy E. Puhy sold 6,364 shares of ABIOMED stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $179.08, for a total value of $1,139,665.12. Following the transaction, the director now directly owns 39,532 shares in the company, valued at $7,079,390.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,646 shares of company stock valued at $4,836,333. Corporate insiders own 7.00% of the company’s stock.

Shares of ABIOMED, Inc. (ABMD) opened at $194.60 on Monday. The stock has a market capitalization of $8,604.43, a PE ratio of 124.74, a price-to-earnings-growth ratio of 2.59 and a beta of 0.16. ABIOMED, Inc. has a 52 week low of $103.53 and a 52 week high of $200.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.20 and a current ratio of 5.84.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.16. The business had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The business’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 EPS. equities research analysts anticipate that ABIOMED, Inc. will post 2.38 earnings per share for the current year.

Several research firms recently commented on ABMD. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective for the company in a report on Tuesday, November 7th. SunTrust Banks reiterated a “buy” rating and issued a $195.00 price objective on shares of ABIOMED in a report on Wednesday, November 1st. BTIG Research reiterated a “hold” rating on shares of ABIOMED in a report on Sunday, October 29th. Piper Jaffray Companies lifted their price objective on ABIOMED to $200.00 and gave the stock an “overweight” rating in a report on Thursday, October 26th. Finally, Leerink Swann restated an “outperform” rating and set a $200.00 price target (up from $180.00) on shares of ABIOMED in a research note on Thursday, October 12th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $185.38.

COPYRIGHT VIOLATION NOTICE: “Bluestein R H & Co. Purchases 20,750 Shares of ABIOMED, Inc. (ABMD)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/04/bluestein-r-h-co-purchases-20750-shares-of-abiomed-inc-abmd.html.

ABIOMED Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply